Emerging Evidence of the Molecular Landscape Specific for Hematogenous Metastasis from Gastric Cancer

Overview

Journal World J Gastrointest Oncol

Publisher Baishideng Publishing Group

Date 2018 Jul 11

PMID 29988904

Citations 12

Authors

Dai Shimizu

Mitsuro Kanda

Yasuhiro Kodera

Affiliations

Soon will be listed here.

Abstract

Gastric cancer (GC) is one of the most frequently diagnosed cancers in the world. Most GC patients are diagnosed when the cancer is in an advanced stage, and consequently, some develop metastatic lesions that generally cause cancer-related death. Metastasis establishment is affected by various conditions, such as tumor location, hemodynamics and organotropism. While digestive cancers may share a primary site, certain cases develop hematogenous metastasis with the absence of peritoneal metastasis, and vice versa. Numerous studies have revealed the clinicopathological risk factors for hematogenous metastasis from GC, such as vascular invasion, advanced age, differentiation, Borrmann type 1 or 2 and expansive growth. Recently, molecular mechanisms that contribute to metastatic site determination have been elucidated by advanced molecular biological techniques. Investigating the molecules that specifically participate in metastasis establishment in distinct secondary organs will lead to the development of novel biomarkers for patient stratification according to their metastatic risk and strategies for preventing and treating distinct metastases. We reviewed articles related to the molecular landscape of hematogenous metastasis from GC.

Citing Articles

Nuclear translocation of cleaved PCDH9 impairs gastric cancer metastasis by downregulating CDH2 expression.

Zhang Y, Zhu Y, Chen Y, Wang Y, Liu B, Pan Y iScience. 2024; 27(2):109011.

PMID: 38357662 PMC: 10865395. DOI: 10.1016/j.isci.2024.109011.

A human stomach cell type transcriptome atlas.

Oling S, Struck E, Noreen-Thorsen M, Zwahlen M, von Feilitzen K, Odeberg J BMC Biol. 2024; 22(1):36.

PMID: 38355543 PMC: 10865703. DOI: 10.1186/s12915-024-01812-5.

Plasma Exosome Proteins ILK1 and CD14 Correlated with Organ-Specific Metastasis in Advanced Gastric Cancer Patients.

Zhou C, Qiao C, Ji J, Xi W, Jiang J, Guo L Cancers (Basel). 2023; 15(15).

PMID: 37568802 PMC: 10417498. DOI: 10.3390/cancers15153986.

HOTAIR Induces the Downregulation of miR-200 Family Members in Gastric Cancer Cell Lines.

Bossaghzadeh F, Hajjari M, Sheikhi A, Salahshourifar I, Irani S Iran Biomed J. 2021; 26(1):77-84.

PMID: 34923813 PMC: 8784900. DOI: 10.52547/ibj.26.1.77.

Hepatic metastasis of gastric cancer is associated with enhanced expression of ethanolamine kinase 2 via the p53-Bcl-2 intrinsic apoptosis pathway.

Miwa T, Kanda M, Shimizu D, Umeda S, Sawaki K, Tanaka H Br J Cancer. 2021; 124(8):1449-1460.

PMID: 33531692 PMC: 8039033. DOI: 10.1038/s41416-021-01271-7.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Allemani C, Weir H, Carreira H, Harewood R, Spika D, Wang X . Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2014; 385(9972):977-1010. PMC: 4588097. DOI: 10.1016/S0140-6736(14)62038-9. View

Kanda M, Kodera Y, Sakamoto J . Updated evidence on adjuvant treatments for gastric cancer. Expert Rev Gastroenterol Hepatol. 2015; 9(12):1549-60. DOI: 10.1586/17474124.2015.1094373. View

Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S . Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res. 2012; 18(21):5992-6000. DOI: 10.1158/1078-0432.CCR-12-1318. View

Shida A, Fujioka S, Ishibashi Y, Kobayashi K, Nimura H, Mitsumori N . Prognostic significance of vascular endothelial growth factor D in gastric carcinoma. World J Surg. 2005; 29(12):1600-7. DOI: 10.1007/s00268-005-0076-z. View

Masuda G, Yashiro M, Kitayama K, Miki Y, Kasashima H, Kinoshita H . Clinicopathological Correlations of Autophagy-related Proteins LC3, Beclin 1 and p62 in Gastric Cancer. Anticancer Res. 2016; 36(1):129-36. View

Shida A, Fujioka S, Kobayashi K, Ishibashi Y, Nimura H, Mitsumori N . Expression of vascular endothelial growth factor (VEGF)-C and -D in gastric carcinoma. Int J Clin Oncol. 2006; 11(1):38-43. DOI: 10.1007/s10147-005-0528-3. View

Grunnet M, Mau-Sorensen M, Brunner N . Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review. Scand J Gastroenterol. 2013; 48(8):899-905. DOI: 10.3109/00365521.2013.812235. View

Tanaka H, Kanda M, Koike M, Iwata N, Shimizu D, Ezaka K . Adherens junctions associated protein 1 serves as a predictor of recurrence of squamous cell carcinoma of the esophagus. Int J Oncol. 2015; 47(5):1811-8. DOI: 10.3892/ijo.2015.3167. View

10.

Ohyama S, Yonemura Y, Kimura H, Kosaka T, Miyazaki I, Sasaki T . Proliferation-associated nuclear antigen p105 as a marker for metastasis of human gastric cancer. J Cancer Res Clin Oncol. 1991; 117(6):583-6. DOI: 10.1007/BF01613292. View

11.

Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K . Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2009; 21(1):67-70. DOI: 10.1093/annonc/mdp260. View

12.

Yamaguchi A, Goi T, Yu J, Hirono Y, Ishida M, Iida A . Expression of CD44v6 in advanced gastric cancer and its relationship to hematogenous metastasis and long-term prognosis. J Surg Oncol. 2002; 79(4):230-5. DOI: 10.1002/jso.10082. View

13.

Kanda M, Kodera Y . Molecular mechanisms of peritoneal dissemination in gastric cancer. World J Gastroenterol. 2016; 22(30):6829-40. PMC: 4974582. DOI: 10.3748/wjg.v22.i30.6829. View

14.

Buchheit C, Weigel K, Schafer Z . Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression. Nat Rev Cancer. 2014; 14(9):632-41. DOI: 10.1038/nrc3789. View

15.

Kruger A, Fata J, Khokha R . Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice. Blood. 1997; 90(5):1993-2000. View

16.

Deryugina E, Quigley J . Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006; 25(1):9-34. DOI: 10.1007/s10555-006-7886-9. View

17.

Yamamoto T, Seino Y, Fukumoto H, Koh G, Yano H, Inagaki N . Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun. 1990; 170(1):223-30. DOI: 10.1016/0006-291x(90)91263-r. View

18.

Oka M, Yamamoto K, Takahashi M, Hakozaki M, Abe T, Iizuka N . Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res. 1996; 56(12):2776-80. View

19.

Holten-Andersen M, Stephens R, Nielsen H, Murphy G, Christensen I, Brunner N . High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res. 2000; 6(11):4292-9. View

20.

Jo M, Jung S . Engineering therapeutic antibodies targeting G-protein-coupled receptors. Exp Mol Med. 2016; 48:e207. PMC: 4892866. DOI: 10.1038/emm.2015.105. View